Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- EDP1815
- DrugBank Accession Number
- DB16486
- Background
EDP1815, was investigated in several clinical trials (NCT05066373, NCT05439941, NCT05682222, NCT03733353, NCT04603027, NCT04488575, NCT05121480, NCT04393246) to evaluate its safety and efficacy in conditions such as gastrointestinal behavior, atopic dermatitis, psoriasis, skin inflammation, and COVID-19.
- Type
- Biotech
- Groups
- Investigational
- Synonyms
- Not Available
- External IDs
- EDP1815
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
EDP1815, a monoclonal microbial product, is a candidate for inflammatory diseases. Developed by Evelo Biosciences, EDP1815 limited inflammatory cytokines associated with psoriasis in a Phase1b clinical trial. In preclinical models, EDP1815 reduced inflammation associated with Th1, Th2, and Th17 pathways, leading to down-regulation of many cytokines implicated in COVID-19-induced cytokine storm. The compound is currently being investigated as an immunomodulator against COVID-19 in comparison to approved cario-pulmonary drugs in a randomized control trial.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- X77JS5APF5
- CAS number
- Not Available
References
- General References
- Lu IN, Kulkarni S, Fisk M, Kostapanos M, Banham-Hall E, Kadyan S, Bond S, Norton S, Cope A, Galloway J, Hall F, Jayne D, Wilkinson IB, Cheriyan J: muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial. Trials. 2020 Jul 31;21(1):690. doi: 10.1186/s13063-020-04618-2. [Article]
- External Link [Link]
- External Link [Link]
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Atopic Dermatitis 1 somestatus stop reason just information to hide 2 Completed Treatment Psoriasis / Psoriasis Vulgaris (Plaque Psoriasis) 1 somestatus stop reason just information to hide 2 Terminated Treatment Atopic Dermatitis 1 somestatus stop reason just information to hide 2 Terminated Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide 2, 3 Completed Treatment Coronavirus Disease 2019 (COVID‑19) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at January 21, 2021 01:47 / Updated at July 19, 2024 10:02